Christopher Nevala-Plagemann
( out of 157 reviews )

Christopher Nevala-Plagemann, MD, MSCI

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Gastrointestinal
Salt Lake City
801-585-0250

Sugar House Health Center

Salt Lake City
801-581-2000

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 157 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    March 21, 2025
    SUGAR HOUSE HEALTH CENTER

    He is very caring and kind

    March 20, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr Nevala-Plagemann is great. He listens to my concerns, celebrates my wins and helps find solutions. I feel that he is a great partner in my health care.

    March 15, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr Nevala has been outstanding in every regard throughout my treatment program at Huntsman. Excellence !

    March 12, 2025
    SUGAR HOUSE HEALTH CENTER

    I have great confidence in Dr. Nevala-Plageman. I feel he is on top of all the latest treatments and especially to my condition. He is friendly and caring. I recommend him highly.

    February 20, 2025
    SUGAR HOUSE HEALTH CENTER

    Very professional . caring .

    February 14, 2025
    SUGAR HOUSE HEALTH CENTER

    Dr. Nevala-Plagemann is amazing. I am thankful for his kindness and considerate care he gives.

    February 12, 2025
    SUGAR HOUSE HEALTH CENTER

    Aloha - GREAT communicator, Very honest up front, and most of all very, very caring about you as a person rather than just a # or a in & out patient. Bedside manner is something you only read about in books & articles -he's amazing!!!

    February 08, 2025
    HUNTSMAN CANCER CENTER

    Dr.Nevala is a great Doctor who really cares. Explains everything so you understand exactly what the issues are and gives you all options that are available

    January 23, 2025
    SUGAR HOUSE HEALTH CENTER

    Very understanding. Klowegable. Vary pleasant.

    See More Patient Comments

  • Chris Nevala-Plagemann is an Assistant Professor of Oncology in the Department of Medicine at the Huntsman Cancer Institute at the University of Utah. He is a board certified medical oncologist with a clinical focus on patients with gastrointestinal cancers.

    Dr. Nevala-Plagemann’s current research is focused on utilizing information contained in large real-world databases to find better ways to treat patients with gastrointestinal cancers using currently available treatments. He is also actively involved in clinical trials at HCI with a goal of identifying novel ways to improve the lives of his patients.

    Prior to joining faculty at HCI, Dr. Nevala-Plagemann received his medical degree from the University of Minnesota. During his medical training he worked in a lab at the University of Minnesota Stem Cell institute where his research focused on gene editing using the CRISPR/cas9 system. Following his undergraduate medical training he moved to Salt Lake City where he completed his internal medicine residency, medical oncology fellowship, and a Master of Science in Clinical Investigation degree here at the University of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Graduate Training Clinical Investigation - University of Utah School of Medicine M.S.
    Fellowship Medical Oncology - University of Utah School of Medicine Fellow
    Residency Internal Medicine - University of Utah School of Medicine Resident
    Professional Medical Medicine - University of Minnesota Medical School M.D.
    Undergraduate Biology - Luther College B.A.

    Selected Publications

    Journal Article

    1. Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V (2025). KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Network Open, 8(1), e2453588-e2453588.
    2. Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I (2022). Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res, 29(17), 3408-3417. (Read full article)
    3. Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I (2022). A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 21(3), 257-264. (Read full article)
    4. Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I (2022). Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer, 22(1), 1054. (Read full article)
    5. Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I (2022). Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Netw, 20(3), 268-275. (Read full article)
    6. Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Netw, 20(2), 144-150. (Read full article)
    7. Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I (2021). Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas, 50(6), 796-802. (Read full article)
    8. Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I (2021). Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Netw, 19(5), 478-482. (Read full article)
    9. Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I (2019). Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open, 4(4), e000539. (Read full article)
    10. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol.
    11. Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I (2018). Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 3(5), e000386. (Read full article)
    12. Nevala-Plagemann C, Lee C, Tolar J (2015). Placenta-based therapies for the treatment of epidermolysis bullosa. Cytotherapy, 17(6), 786-795. (Read full article)

    Review

    1. Iyengar S, Nevala-Plagemann C, Garrido-Laguna I (2021). Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. [Review]. Ther Adv Med Oncol, 13, 17588359211045861. (Read full article)
    2. Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I (2021). Emerging Treatment Strategies in Metastatic Pancreatic Cancer. [Review]. Pancreas, 50(6), 773-787. (Read full article)
    3. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I (2019). From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. [Review]. Nat Rev Clin Oncol, 17(2), 108-123. (Read full article)

    Case Report

    1. Rubnitz Z, Nevala-Plagemann CD, Florou V, Garrido-Laguna I (2025). Gemcitabine-induced myositis in a patient with pancreatic cancer. BMJ Case Rep, 18(1), e259660.
    2. Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I (2023). Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol, 14(6), 2637-2643. (Read full article)
    3. Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I (2020). Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol, 4. (Read full article)
    4. Nevala-Plagemann C, Powers P, Mir-Kasimov M, Rose R (2019). A Fatal Case of Septic Shock Secondary to Acinetobacter Bacteremia Acquired from a Platelet Transfusion. Case Rep Med, 2019, 3136493. (Read full article)

    Editorial

    1. Nevala-Plagemann CD, Garrido-Laguna I (2024). NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? 21(8), 567-568.

    Abstract

    1. Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I (2020). Treatment trends and clinical outcomes of left sided, RAS/RAF wild type metastatic colorectal cancer in the United States [Abstract]. 31(4), 438.

  • News & Podcasts

    Huntsman Cancer Institute News